70% of classic homocystinuria patients are unhappy with their treatment (MARKETVUE® REPORT)Danielle Drayton2023-05-08T11:48:19+00:00May 8th, 2023|Read More
1 in 3 pemphigoid patients not well-managed on current treatments (MARKETVUE® REPORT)Danielle Drayton2023-05-08T11:47:18+00:00May 8th, 2023|Read More
MARKETVUE® REPORT: 60% of ANCA-associated vasculitis U.S. clinicians report Amgen’s Tavneos’ steroid-sparing ability and remission times as impressiveDanielle Drayton2023-05-08T11:43:35+00:00May 8th, 2023|Read More
MARKETVUE® REPORT: Frontal Fibrosing Alopecia burden of disease is significant with half of patients unable to achieve complete response to treatmentDanielle Drayton2023-05-08T11:42:04+00:00May 8th, 2023|Read More
70% of classic homocystinuria patients are unhappy with their treatment (MARKETVUE® REPORT)Danielle Drayton2023-05-08T11:48:19+00:00May 8th, 2023|Read More
1 in 3 pemphigoid patients not well-managed on current treatments (MARKETVUE® REPORT)Danielle Drayton2023-05-08T11:47:18+00:00May 8th, 2023|Read More
MARKETVUE® REPORT: 60% of ANCA-associated vasculitis U.S. clinicians report Amgen’s Tavneos’ steroid-sparing ability and remission times as impressiveDanielle Drayton2023-05-08T11:43:35+00:00May 8th, 2023|Read More
MARKETVUE® REPORT: Frontal Fibrosing Alopecia burden of disease is significant with half of patients unable to achieve complete response to treatmentDanielle Drayton2023-05-08T11:42:04+00:00May 8th, 2023|Read More
